Slide Library

DERMATOLOGY

BIMZELX^® (bimekizumab-bkzx) is now FDA approved for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). See the phase 3 clinical trial data in Publications.

UCB continues to proactively monitor the COVID-19 situation. To learn more about UCB's preparedness, click here.

RHEUMATOLOGY

The Women's Health Fellowship Program application is now closed. Learn More

Bimekizumab in Axial Spondyloarthritis (AxSpA)

Bimekizumab in Hidradenitis Suppurativa (HS)

Bimekizumab in Psoriatic Arthritis (PsA)

EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2023 Update

The IL-17 Story: All in the Family